Novel Rx
Nouf Al hemmadi
1 year 10 months ago
ACR convergence highlights by the awesome, i mean very awesome team @RheumNow
Sunday to Thursday with recap Friday 🤓 i am stocking every one😂
https://t.co/WahAoH7MCM
Biologic / target synthetic induced None melanoma skin cancer? Disease induced or medication induced ?
David Liew drdavidliew
1 year 10 months ago
I never tire of hearing this story.
Biologic DMARDs revolutionized rheumatology & changed millions of lives.
How did we get TNFi?
Sharp translational insights & courage++
After 4w, RA gone, up/down stairs like a miracle.
Sir Ravinder 'Tiny' Maini #ACR23 Global Summit @RheumNow https://t.co/Je1cz3cWG5
In a post hoc analysis of the phase 2 NOBILITY trial, researchers found that treatment with obinutuzumab—an antibody that targets a protein expressed on certain immune cells—was superior to placebo for preserving kidney function and preventing flares in patients with lupus nephritis, a kidney condition associated with the autoimmune disease lupus.
TheDaoIndex KDAO2011
1 year 10 months ago
Big Pharma – Pay attention! When developing new therapeutics, consider delivery, cost, climate sensitivity and sustainability #GlobalSummit @ACRheum @rheumnow #ACR23 https://t.co/ThqnTI3SNm
TheDaoIndex KDAO2011
1 year 10 months ago
Opportunities to address healthcare inequities: generics/biosimilars, fair pricing, and inclusive business models. #GlobalSummit @RheumNow #ACR23 @ACRheum https://t.co/ynJWWcCqWo
Dr. John Cush RheumNow
1 year 10 months ago
Long term results of the MAINRITSAN study (Maintenance Remission w/ RTX in Systemic AAV) showed fixed-schedule RTX superior to AZA in preventing major relapses at 84mos (HR 0.38), but tailored-RTX assoc w/ incr risk of major relapse (HR 2.92) https://t.co/xLxvPCsRC9 https://t.co/mWwo7GgCIq
Dr. John Cush RheumNow
1 year 10 months ago
Biologics, #RA and Risk of skin CA (NMSC) is complex.
- RA alone is a risk for NMSC
49K study of ABA & NMSC ;
- In RCTs, risk same w/ ABA & PBO
- Registries & Claims data: equal w/ ABA, csDMARDs. b/tsDMARDs
- Pooled obs data shows slight ABA risk https://t.co/tp6F0cJWug https://t.co/u6UdAUZqoc
I recently overheard a very good practicing rheumatologist complain, “why do I need yet another drug for psoriatic arthritis? I have more treatment choices than I have actual PsA patients who need a new or better drug”.
A prospective study of first line use anakinra in systemic juvenile idiopathic arthritis (sJIA) proved to be effective and without potentially allergic lung reactions.
Dr. John Cush RheumNow
1 year 10 months ago
New download available, titled "Dealing with Infections"
https://t.co/hsOuJoFokg https://t.co/G3MZ9BQo0X
Dr. John Cush RheumNow
1 year 10 months ago
FDA has approved secukinumab (Cosentyx) for use in adults w/ moderate to severe hidradenitis suppurativa. Recommended dose is 300 mg SC @ wk 0, 1, 2, 3 and 4 and then every 4 weeks thereafter. https://t.co/4f6Ew5KGmg https://t.co/SldJ6MXMw7 https://t.co/KfCww7doef
Dr. John Cush RheumNow
1 year 10 months ago
Analysis of German RABBIT registry did not show more MACE events in pts w/ JAK inhibitors compared to other DMARDs. 154 MACE w/ 14203 Rx episodes (21218 Pt-Yrs). IRs were 0.68 JAKi, 0.62 TNFi, 0.76 bdMARDs and 0.95 csDMARDs; higher in CV risk pts https://t.co/luUK9M9IM9 https://t.co/z8lxjWscCR
Dr. John Cush RheumNow
1 year 10 months ago
Metanalysis of 26 studies (2252) pts w/ HBsAg-/HBcAb+ RA treated with b/tsDMARDs, shows the pooled HBV reactivation rate was 2.0%
HBV reactivation higher w/ RTX (9%), ABA (6%), JAKi (1%); none w/ IL-6i or TNF-i
More reactivation if pt is HBsAb- (OR=4.56) https://t.co/V60nkUSpjj https://t.co/jnZKnY0Zuk
Dr. John Cush RheumNow
1 year 10 months ago
FDA Approves Infliximab Biosimilar for Subcutaneous Use
Another infliximab biosimilar has been FDA approved, but this new version of Inflectra can be given subcutaneously for patients with inflammatory bowel disease.
https://t.co/oTGm16k6Uo https://t.co/tSysmriP7q https://t.co/TIZc8rxwxM
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week on RheumNow.com.
Study of LATE-onset RA (>65y), shows DMARD initiation is low in LORA; despite current clinical practice guidelines recommending early aggressive Rx. Among 3,373 LORA pts (age77 yrs), only 29% initiated on a DMARD. https://bit.ly/47dT6x6
Poster Hall